[{"address1": "4960 Peachtree Industrial Boulevard", "address2": "Suite 240", "city": "Norcross", "state": "GA", "zip": "30071", "country": "United States", "phone": "678 620 3186", "website": "https://galectintherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.", "fullTimeEmployees": 15, "companyOfficers": [{"maxAge": 1, "name": "Mr. Joel  Lewis CPA", "age": 54, "title": "President, CEO & Director", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 987039, "exercisedValue": 0, "unexercisedValue": 12600}, {"maxAge": 1, "name": "Mr. Jack W. Callicutt CPA", "age": 57, "title": "CFO, Treasurer & Corporate Secretary", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 572205, "exercisedValue": 0, "unexercisedValue": 9000}, {"maxAge": 1, "name": "Dr. Khurram  Jamil M.D.", "age": 48, "title": "Chief Medical Officer", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 620529, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert  Tritt J.D.", "title": "General Counsel", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jim  Wilkins Ph.D.", "title": "Head of CMC & Pharmaceutical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Beth  Knowles", "title": "Executive Assistant & Officer Manager", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 6.16, "open": 4.59, "dayLow": 3.8, "dayHigh": 4.83, "regularMarketPreviousClose": 6.16, "regularMarketOpen": 4.59, "regularMarketDayLow": 3.8, "regularMarketDayHigh": 4.83, "payoutRatio": 0.0, "beta": 0.96, "forwardPE": -2.607143, "volume": 4104407, "regularMarketVolume": 4104407, "averageVolume": 393461, "averageVolume10days": 712610, "averageDailyVolume10Day": 712610, "bid": 5.12, "ask": 8.4, "bidSize": 2, "askSize": 2, "marketCap": 282418944, "fiftyTwoWeekLow": 0.76, "fiftyTwoWeekHigh": 7.13, "allTimeHigh": 38.28, "allTimeLow": 0.3, "fiftyDayAverage": 5.5492, "twoHundredDayAverage": 3.3331, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 399132832, "profitMargins": 0.0, "floatShares": 45699604, "sharesOutstanding": 64472792, "sharesShort": 6816789, "sharesShortPriorMonth": 6903772, "sharesShortPreviousMonthDate": 1761868800, "dateShortInterest": 1764288000, "sharesPercentSharesOut": 0.10569999, "heldPercentInsiders": 0.29778, "heldPercentInstitutions": 0.16044001, "shortRatio": 16.46, "shortPercentOfFloat": 0.1497, "impliedSharesOutstanding": 64479210, "bookValue": -1.951, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -37442000, "trailingEps": -0.59, "forwardEps": -1.68, "lastSplitFactor": "1:6", "lastSplitDate": 1332460800, "52WeekChange": 5.921348, "SandP52WeekChange": 0.1340276, "quoteType": "EQUITY", "currentPrice": 4.38, "targetHighPrice": 11.0, "targetLowPrice": 11.0, "targetMeanPrice": 11.0, "targetMedianPrice": 11.0, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 1, "totalCash": 11525000, "totalCashPerShare": 0.179, "totalDebt": 126054000, "quickRatio": 0.084, "currentRatio": 0.093, "returnOnAssets": -0.87087995, "freeCashflow": -24144376, "operatingCashflow": -30624000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "GALT", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1031146200000, "postMarketChangePercent": -0.6849363, "postMarketPrice": 4.35, "postMarketChange": -0.03000021, "regularMarketChange": -1.78, "regularMarketDayRange": "3.8 - 4.83", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 393461, "epsTrailingTwelveMonths": -0.59, "epsForward": -1.68, "fiftyDayAverageChange": -1.1692, "fiftyDayAverageChangePercent": -0.21069703, "twoHundredDayAverageChange": 1.0469, "twoHundredDayAverageChangePercent": 0.31409198, "priceToBook": -2.2450027, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "fiftyTwoWeekLowChange": 3.6200001, "fiftyTwoWeekLowChangePercent": 4.7631583, "fiftyTwoWeekRange": "0.76 - 7.13", "fiftyTwoWeekHighChange": -2.75, "fiftyTwoWeekHighChangePercent": -0.38569424, "fiftyTwoWeekChangePercent": 592.1348, "earningsTimestampStart": 1754915400, "earningsTimestampEnd": 1755261000, "isEarningsDateEstimate": true, "regularMarketChangePercent": -28.8961, "regularMarketPrice": 4.38, "exchange": "NCM", "messageBoardId": "finmb_1065415", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "prevName": "Galectin Therapeutics, Inc.", "nameChangeDate": "2025-12-19", "averageAnalystRating": "1.0 - Strong Buy", "cryptoTradeable": false, "shortName": "Galectin Therapeutics Inc.", "longName": "Galectin Therapeutics Inc.", "corporateActions": [], "postMarketTime": 1766192393, "regularMarketTime": 1766178001, "displayName": "Galectin Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-12-20"}]